Skip to main content
. 2019 Sep 17;18(5):4022–4030. doi: 10.3892/etm.2019.8016

Figure 3.

Figure 3.

Effects of PDGF-BB on the Janus kinase 2/STAT3 signaling pathway and CXCR4 and CXCR7 expression in pericytes. (A-D) Pericytes were first treated with PDGF-BB (10 ng/ml) for 0, 24, 48 and 72 h. (A) STAT3, (B) ERK1/2 and (C) AKT phosphorylation were measured by western blotting. (D) PDGF-BB activated STAT3 phosphorylation in a time-dependent manner, but not p-AKT or p-ERK1/2. (E and F) Pericytes were first pretreated with niclosamide (a STAT3 inhibitor) at 1 µM for 1 h and then with PDGF-BB (10 ng/ml) for 24 h. (E) CXCR4 and (F) CXCR7 mRNA expression were subsequently measured using reverse transcription-quantitative PCR. Data are resented as means ± SD from three independent experiments. *P<0.05 vs. untreated cells or PDGF-BB and **P<0.01 vs. untreated cells. CXCR, C-X-C motif chemokine receptor; PDGF-BB, platelet-derived growth factor-BB.